Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond

Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).

Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.

Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.

Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.

The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.

Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.